Physician profile
Jonathan Theo
NPI 1164919379
$16,317.89
in general payments reported to CMS, 2019-2025
17 companies · $301 in 2025
The $301 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $13K · 2023: $2,237 · 2024: $1,239 · 2025: $301.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,029 · Travel and Lodging: $962 · Consulting Fee: $675 · Education: $111.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,028.97 |
| Travel and Lodging | $962.49 |
| Consulting Fee | $675.00 |
| Education | $111.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $11,248.75 | 2022-2025 | Percept PC Brainsense, Activa PC |
| Boston Scientific Corporation | $1,685.77 | 2023-2024 | Vercise |
| Abbvie INC. | $1,010.32 | 2022-2025 | Duopa, Botox |
| Amneal Pharmaceuticals LLC | $836.57 | 2022-2023 | Rytary |
| Amgen INC. | $370.25 | 2023-2025 | Repatha, Repatha |
| Abbott Laboratories | $299.42 | 2023-2024 | Infinity |
| Acadia Pharmaceuticals INC | $282.62 | 2022-2024 | Nuplazid |
| Merz Pharmaceuticals, LLC | $168.77 | 2022-2023 | Xeomin |
| Teva Pharmaceuticals USA, INC. | $147.04 | 2023-2024 | Austedo Xr |
| Kyowa Kirin, INC. | $90.18 | 2022-2023 | Nourianz |
| Avion Pharmaceuticals | $50.55 | 2023 | Dhivy |
| Ge Healthcare | $38.16 | 2023-2025 | |
| Allergan, INC. | $20.03 | 2022 | |
| Lundbeck LLC | $19.92 | 2024 | Vyepti |
| Lilly USA, LLC | $17.49 | 2023 | Reyvow, Emgality |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $16.61 | 2023 | |
| Pfizer INC. | $15.44 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Theo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.